Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Tue, 01.09.2026       Limes Schlosskliniken AG

Company Name: Limes Schlosskliniken AG ISIN: DE000A0JDBC7   Reason for the research: Update Recommendation: BUY Target price: EUR 810 Target price on sight of: 12 months Last rating change: Analyst: Philipp Sennewald H1 confirms the case, FCF set to grow strongly; chg. Yesterday, LIMES published its H1'25 report, showing continue [ … ]
Tue, 01.09.2026       https://research-hub.de/companies/symrise-ag

Symrise has completed the divestment of AmeriTerpenes, its U.S. terpene ingredients business with c. USD 200m of annual revenues, to Mutares. We view the transaction as a modest positive for portfolio quality, as it reduces exposure to a more commodity-like business while preserving supply continuity through long-term commercial agreements. Financial terms were not disclosed and Symrise expects a mid-double-digit EUR million non-cash disposal loss in FY26, leaving limited implications for our forecasts. The key trigger for a more constructive view remains a durable reacceleration in organic growth, which we continue to see as challenging given the macroeconomic backdrop and uneven demand trends. With valuation broadly fair, we reiterate HOLD and our EUR 100.00 PT. The full update can be downloaded under https://research-hub.de/companies/symrise-ag
Tue, 01.09.2026       https://research-hub.de/companies/verbio-se

With immediate effect, we are discontinuing coverage of “Verbio SE”. Our price target, estimates and valuation are no longer valid. The full update can be downloaded under https://research-hub.de/companies/verbio-se
Tue, 01.09.2026       https://research-hub.de/companies/hellofresh-se

We revisited HelloFresh’s customer dynamics and believe that improving engagement among existing customers is still not enough to offset the weak inflow of new customers. Group average order value (AOV) rose 6.5% cc, while orders fell 13.7%, leaving volumes under continued pressure. The currently weak customer acquisition means fewer customers can mature into the valuable tenured cohorts that increasingly underpin Meal Kit revenues, potentially extending the recovery timeline and creating a drag on the revenue base. We still expect a gradual normalization in customer acquisition, albeit more modestly than previously assumed, leaving continued top-line pressure to weigh on earnings. We moderate our long-term growth assumptions. Our DCF-based price target falls to EUR 2.90 from EUR 3.30; HOLD. The full update can be downloaded under https://research-hub.de/companies/hellofresh-se
Tue, 01.09.2026       https://research-hub.de/companies/geratherm-medical-ag

At the Frankfurt Equity Forum, CEO Christian Frick detailed Geratherm’s strategic realignment following challenging H1 26 results, characterized by price competition from Chinese manufacturers and pharmacy private-label shifts. In response, glass furnace operations are now shifting to pooled campaigns, allowing longer shutdowns to save energy costs. Geratherm has also completed EU Medical Devices Regulation (MDR) recertification for the complete product lineup. Portfolio adjustments continue, supported by EUR 8.8m in liquid assets and securities. We reiterate our BUY rating with a EUR 4.00 target price. The full update can be downloaded under https://research-hub.de/companies/geratherm-medical-ag
Mon, 31.08.2026       https://research-hub.de/companies/airbus-se

We refresh our Airbus delivery tracking ahead of the final delivery release in early September. Based on our tracking, Airbus has delivered c. 466 commercial aircraft through 29 August, excluding any handovers on the 30th and 31st August, 7% ahead of the same point in 2025. On that basis, Airbus needs 404 deliveries in the final four months, 11% above the previous four-month record of 363, set in 2019. Supportive factors include a December ramp that has grown for straight three years, and Airbus' track record of clearing year-end bars that looked out of reach back in September. We keep 870 deliveries in FY26E, our BUY and our PT of EUR 227. The full update can be downloaded under https://research-hub.de/companies/airbus-se
Mon, 31.08.2026       https://research-hub.de/companies/draegerwerk-ag-co-kgaa

Dräger’s recent performance reinforces our confidence in a structural margin improvement story, supported by higher gross margins, disciplined cost management and operating leverage. Safety remains the key earnings driver, while Medical offers further normalization potential. Even excluding c. EUR 29m of tariff reimbursements, we estimate an underlying FY26 EBIT margin of ~6.8%. Management’s FY26 guidance of 2-6% currency-adjusted revenue growth and a 6-8% EBIT margin remains on track. Q3 results and the November CMD in Luebeck are the next key proof points. We raise our medium-term margin assumptions, increase our price target to EUR 130 from EUR 114, and reiterate our BUY. The full update can be downloaded under https://research-hub.de/companies/draegerwerk-ag-co-kgaa
Mon, 31.08.2026       Verbio SE

Company Name: Verbio SE ISIN: DE000A0JL9W6   Reason for the research: Initiation Recommendation: BUY Target price: EUR 41 Target price on sight of: 12 months Last rating change: Analyst: Jorge Gonzalez Renewable fuels entering a new cycle; INITIATE WITH BUYVERBIO is one of Europe's leading integrated biorefineries, converting agr [ … ]
Mon, 31.08.2026       https://research-hub.de/companies/duerr-ag

Duerr AG’s presentation at German Select VIII reinforced a broadly unchanged investment case. Core Automotive performance remains solid and Woodworking is navigating a soft market with improving margins. However, BBS Automation remains the primary operational drag. Duerr confirmed its FY26 guidance, targeting order intake of EUR 3.8-4.2bn, sales of EUR 3.9-4.3bn, and an EBIT margin b.e.e. of 5.0-6.5%. With H1 delivering resilient underlying performance despite macro headwinds, the key debate centers on the execution of the Vector restructuring program at BBS and Duerr’s ability to achieve its ≥8% mid-cycle margin target. We reiterate our BUY rating with a PT of EUR 32.00. The full update can be downloaded under https://research-hub.de/companies/duerr-ag
Fri, 28.08.2026       Verve Group SE

Company Name: Verve Group SE ISIN: SE0018538068   Reason for the research: Q2 Bericht Recommendation: Kaufen from: 28.08.2026 Target price: €4 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu Verve Group SE (ISIN: SE0018538068) veröf [ … ]

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

© 2026 Select Sector SPDRs

* * *

More Sector related Investment Ideas
© 2026 WEBs Investments ETFs
Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 22.11.2026, Calendar Week 47, 326th day of the year, 39 days remaining until EoY.